PF-Atlas › Weekly Digest

Weekly IPF Research Digest

A short, plain-language recap of IPF research, one issue a week. Tap an issue to read the full digest.

Get IPF progress updates by email

This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.

We email a confirmation link first, so it is really you. No spam, ever.
Two New Phase II Trials Enter the IPF Pipeline as Research Activity Stays HighNew
November 9 to 16, 2026 · Active week
Nov 9 to 16 2026: two new Phase II trials, 12 new papers, one key study on lung tissue regeneration, and our solver…
Read the full digest →
A New Real-World Nerandomilast Study Opens, Lung Scarring Cell Biology Gets Clearer, and Our Own AI Solver Tests 20 Drug Cocktails
November 2 to 9, 2026 · Active week
IPF digest Nov 2 to 9, 2026: one new trial recruiting, 12 new papers, and PF-Atlas's own solver ran 20 experimental…
Read the full digest →
Nerandomilast Gets Its Close-Up, Our Solver Reaches 19 Candidates, and Twelve New Papers Land
October 26 to November 2, 2026 · Active week
A busy research week for IPF: a study on nerandomilast, twelve new papers, and our own AI solver now tracking 19…
Read the full digest →
Lung Cell Flexibility, Genetic Risk Across Populations, and Our Solver's Best Formula Yet: IPF Week of Oct 19 to 26, 2026
October 19 to 26, 2026 · Active week
This week brings 12 new IPF papers, a fascinating lung cell study, and our own solver's top 5-drug cocktail hypothesis.…
Read the full digest →
A New Inhaled Drug Enters Testing, a Fat-Protein Finding Surprises Researchers, and Our Own Software Explores 134 Drug Combinations
October 12 to 19, 2026 · Active week
Oct 12 to 19, 2026: one new Phase 1 trial, two trial status updates, 12 new papers, and PF-Atlas's solver runs 134 drug…
Read the full digest →
Four New Trials Open, Inhaled Treprostinil Debated in NEJM, and Our Solver Hits 133 Combinations
October 5 to 12, 2026 · Active week
IPF week of Oct 5 to 12, 2026: four trials launch, NEJM letters debate inhaled treprostinil, and PF-Atlas's own solver…
Read the full digest →
New Phase 2 and Phase 3 Trials Open, Stem Cell Exosome Study Earns Study of the Week
October 3 to 10, 2026 · Active week
Oct 3 to 10, 2026: four new IPF trials open, letters debate inhaled treprostinil, and our software flags four new drug…
Read the full digest →
IPF Research Digest, September 27 to October 4, 2026: Twelve New Papers, No New Trials, and Four Computer-Generated Hypotheses From Our Own Software
September 27 to October 4, 2026 · Active week
A busy week for lab science in IPF, with twelve new papers published, no new clinical trials opened, and our own AI…
Read the full digest →
PDE4 Inhibitors in the Spotlight, a New Breathing Trial Opens, and Our AI Flags Three Inhaled Drug Candidates
September 15 to 22, 2026 · Active week
Sept 15 to 22, 2026: one new IPF trial opens, twelve papers land, and PF-Atlas software surfaces three experimental…
Read the full digest →
Medical disclaimer. This digest summarizes public clinical-trial and research data in plain language for information only. It is not medical advice, a treatment recommendation, or a promise of any outcome. Evidence changes; treatments described as investigational are not proven cures. Always verify with ClinicalTrials.gov, PubMed and a qualified pulmonologist before any decision.